| #高警訊藥品 |
胃癌、胰臟癌
Gastric cancer:
Treatment of disseminated adenocarcinoma of the stomach (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.
Pancreatic cancer:
Treatment of disseminated adenocarcinoma of the pancreas (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.
* Limitations of use: Not recommended for single-agent primary therapy or to replace appropriate surgery and/or radiotherapy in the treatment of these conditions.
Mitomycin alkylates DNA to produce DNA cross-linking (primarily with guanine and cytosine pairs) and inhibits DNA and RNA synthesis. Mitomycin is not cell cycle specific but has its maximum effect against cells in late G and early S phases.
2. Half-life elimination: 17 minutes (30 mg dose)
3. Excretion: Feces; Urine
2. Thrombocytopenia; Coagulation disorders,or other increased bleeding tendency
2.Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.
1. Gastrointestinal: Anorexia, nausea, vomiting
2. Hematologic & oncologic: Bone marrow depression, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura
3. Miscellaneous: Fever
Postmarketing:
Adult respiratory distress syndrome (ARDS), bladder spasm, cardiac failure, dyspnea, extravasation reactions, hepatic sinusoidal obstruction syndrome, interstitial fibrosis, malaise, nonproductive cough, pulmonary infiltrates, renal failure, skin rash, weakness
2. Continuous ambulatory peritoneal dialysis (CAPD): Reduce dose to 75% of usual dose.
靜脈注射、動脈內注射、肋膜腔內注射、腹腔內注射或膀胱灌注。
Intravenous (IV), intra-arterial (IA), intrapleural, intraperitoneal injection, or intravesical instillation.
0.9% 生理食鹽水。
0.9% Normal Saline.
每 2 mg 之 Mitomycin-C 使用 5 ml 生理食鹽水溶解（10 mg 藥瓶需 25 ml 稀釋液）。
Reconstitute each 2 mg of Mitomycin-C with 5 ml of Normal Saline (25 ml for a 10 mg vial).
注射速度應緩慢。
Injection speed should be slow.
Standard instructions do not specify refrigerated stability after dilution. (仿單未載明稀釋於輸液後之冷藏安定性數據。)、給藥前後應以5-10 ml輸注溶液沖洗靜脈管路
1. 外滲處置：本藥具強烈發皰性，藥液滲出血管外會導致注射部位硬結或壞死，注射時須極為小心。 2. 安定性注意：藥效會隨 pH 值降低而減弱，pH 7.0 以下即不穩定。 3. 安全監測：可能引起嚴重的骨髓抑制、腎功能衰竭或溶血性尿毒症，應定期監測血液相及腎功能。 4. 特殊警語：若出現間質性肺炎或肺纖維化症狀，應立即停藥並採取處置。
1. Extravasation: This drug is a potent vesicant; leakage outside the vein can cause induration or necrosis at the injection site. Administer with extreme caution. 2. Stability: Potency decreases at low pH; the drug is unstable if pH is below 7.0. 3. Safety Monitoring: May cause severe bone marrow suppression, renal failure, or hemolytic uremic syndrome; blood counts and renal function must be monitored regularly. 4. Special Warning: If symptoms of interstitial pneumonia or pulmonary fibrosis occur, treatment should be discontinued immediately and managed appropriately.